Amgen
Corporate Headquarters
One Amgen Center Drive
Thousand Oaks
California
91320-1799
United States
Tel: 805-447-1000
Fax: 805-447-1010
Website: http://careers.amgen.com/
Email: talentacquisitioninquiries@amgen.com
About Amgen
We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.
We live the mission.
We win together.
We thrive on continual challenge.
Our team of 22,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.
At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.
Connect with us to explore how you can Win, Live, and Thrive at Amgen.
Defy Imagination
2434 articles about Amgen
-
In its Q2 earnings report, Amgen revealed the demise of two HLE BiTE molecules. Also on Thursday, the company announced it is acquiring ChemoCentryx for $4 billion. -
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
8/4/2022
Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.
-
Amgen Reports Second Quarter 2022 Financial Results
8/4/2022
Amgen announced financial results for the second quarter of 2022.
-
Amgen Appoints Michael V. Drake to Board of Directors
8/3/2022
Amgen announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately.
-
Amgen Announces 2022 Third Quarter Dividend
8/3/2022
Amgen announced that its Board of Directors declared a $1.94 per share dividend for the third quarter of 2022.
-
AMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022
8/2/2022
Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) at 12:00 p.m. ET on Monday, Aug. 8, 2022.
-
AMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS
8/1/2022
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 4, 2022, after the close of the U.S. financial markets.
-
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
7/27/2022
IDEAYA Biosciences, Inc. announced it has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397, its investigational, potential best-in-class, small molecule MAT2A inhibitor, with Amgen's AMG 193, an investigational small molecule MTA-cooperative inhibitor of PRMT5, in a Phase 1 clinical trial.
-
The U.S. Attorney’s Office was busy indicting nine people for charges related to insider trading. Some charges were unrelated, but three were specific to the biopharma industry. -
First report from the worlds most ambitious sequencing project
7/20/2022
Scientists at deCODE genetics a subsidiary of Amgen together with collaborators from Denmark report on the whole genome sequences of 150 thousand participants in the UK biobank in a paper published in the journal Nature.
-
Early data from Amgen's ongoing trial on Lumakras for non-small cell lung cancer hinted at positive results from what could be a transformative combination of drugs versus cancer. -
Last year, the FDA's Center for Drug Evaluation and Research approved 50 drugs. A new study found that 33, or 66% of them, were supported with genomic data. -
AMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE
6/10/2022
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 43rd Annual Healthcare Conference at 1:40 p.m. ET on Wednesday, June 15, 2022.
-
Mirati Therapeutics presented the first clinical data demonstrating CNS-specific activity of a KRASG12C inhibitor in patients with NSCLC with active and untreated CNS metastases. -
FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS
6/6/2022
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
-
New Head-to-head Data Show Vectibix® (Panitumumab) Demonstrated Superior Overall Survival Compared to Bevacizumab in Combination With Chemotherapy in Japanese Patients With Wild-type RAS Colorectal Cancer
6/5/2022
Amgen and Takeda Pharmaceutical Company announced that new data from the Phase 3 PARADIGM clinical trial of Vectibix® in Japanese patients with previously untreated unresectable wild-type RAS metastatic colorectal cancer are being featured during the June 5 Plenary Session of the American Society of Clinical Oncology Annual Meeting being held in Chicago and online.
-
AMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE
6/3/2022
Amgen (NASDAQ:AMGN) will present at the 2022 Jefferies Healthcare Conference at 9:30 a.m. ET on Wednesday, June 8, 2022.
-
Amgen Receives LUNGevity Foundation Hope Award for Corporate Leadership
6/2/2022
LUNGevity recognizes Amgen for its exceptional commitment to lung cancer communities and improving outcomes for people diagnosed with the disease.
-
Amgen and NSG Biolabs Announce Golden Ticket to Boost Singapore's Biotech Ecosystem
6/1/2022
Amgen, a leading global biotechnology company, and NSG BioLabs, Singapore's largest and leading biotechnology incubator, announced the launch of a 3-year Golden Ticket sponsorship.
-
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)
5/31/2022
Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD).